Cargando…

Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma

BACKGROUND & AIMS: The metabolic dysfunction-associated fatty liver disease (MAFLD) is a new inclusive term proposed to replace non-alcoholic fatty liver disease (NAFLD). We analysed whether hepatocellular carcinoma (HCC) risk differs by MAFLD or NAFLD status in a large sample of asymptomatic ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Byeong Geun, Choi, Sung Chul, Goh, Myung Ji, Kang, Wonseok, Sinn, Dong Hyun, Gwak, Geum-Youn, Paik, Yong-Han, Choi, Moon Seok, Lee, Joon Hyeok, Paik, Seung Woon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393797/
https://www.ncbi.nlm.nih.gov/pubmed/37538246
http://dx.doi.org/10.1016/j.jhepr.2023.100810
_version_ 1785083222720249856
author Song, Byeong Geun
Choi, Sung Chul
Goh, Myung Ji
Kang, Wonseok
Sinn, Dong Hyun
Gwak, Geum-Youn
Paik, Yong-Han
Choi, Moon Seok
Lee, Joon Hyeok
Paik, Seung Woon
author_facet Song, Byeong Geun
Choi, Sung Chul
Goh, Myung Ji
Kang, Wonseok
Sinn, Dong Hyun
Gwak, Geum-Youn
Paik, Yong-Han
Choi, Moon Seok
Lee, Joon Hyeok
Paik, Seung Woon
author_sort Song, Byeong Geun
collection PubMed
description BACKGROUND & AIMS: The metabolic dysfunction-associated fatty liver disease (MAFLD) is a new inclusive term proposed to replace non-alcoholic fatty liver disease (NAFLD). We analysed whether hepatocellular carcinoma (HCC) risk differs by MAFLD or NAFLD status in a large sample of asymptomatic adults. METHODS: A cohort comprising 73,691 adults were followed up for the development of HCC. NAFLD was diagnosed among participants without other liver diseases (n = 65,992). RESULTS: Participants with MAFLD showed higher incidence of HCC than those without MAFLD (0.37 and 0.24 per 1,000 person-years, respectively; p = 0.006). However, MAFLD was not an independent factor associated with HCC in multivariable adjusted analysis (hazard ratio [HR] 1.21; 95% CI 0.92–1.60). When stratified according to presence of other liver diseases, MAFLD was not associated with HCC in participants with other liver diseases. In participants without other liver diseases, both MAFLD (adjusted HR 1.84; 95% CI 1.09–3.11) and NAFLD (adjusted HR 1.71; 95% CI 1.01–2.90) were independent factors associated with HCC. When stratified according to NAFLD and MAFLD status, there was no HCC development among participants with NAFLD only during 8,936 person-years of follow-up, but this NAFLD-only group comprised 3.4%, and the majority of participants with hepatic steatosis fulfilled both NAFLD and MAFLD criteria. CONCLUSIONS: In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. For those without other chronic liver diseases, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC. IMPACT AND IMPLICATIONS: This study investigated the usefulness of newly proposed nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD), over non-alcoholic fatty liver disease (NAFLD), in terms of predicting hepatocellular carcinoma. In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. However, for those without chronic liver disease, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC.
format Online
Article
Text
id pubmed-10393797
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103937972023-08-03 Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Song, Byeong Geun Choi, Sung Chul Goh, Myung Ji Kang, Wonseok Sinn, Dong Hyun Gwak, Geum-Youn Paik, Yong-Han Choi, Moon Seok Lee, Joon Hyeok Paik, Seung Woon JHEP Rep Research Article BACKGROUND & AIMS: The metabolic dysfunction-associated fatty liver disease (MAFLD) is a new inclusive term proposed to replace non-alcoholic fatty liver disease (NAFLD). We analysed whether hepatocellular carcinoma (HCC) risk differs by MAFLD or NAFLD status in a large sample of asymptomatic adults. METHODS: A cohort comprising 73,691 adults were followed up for the development of HCC. NAFLD was diagnosed among participants without other liver diseases (n = 65,992). RESULTS: Participants with MAFLD showed higher incidence of HCC than those without MAFLD (0.37 and 0.24 per 1,000 person-years, respectively; p = 0.006). However, MAFLD was not an independent factor associated with HCC in multivariable adjusted analysis (hazard ratio [HR] 1.21; 95% CI 0.92–1.60). When stratified according to presence of other liver diseases, MAFLD was not associated with HCC in participants with other liver diseases. In participants without other liver diseases, both MAFLD (adjusted HR 1.84; 95% CI 1.09–3.11) and NAFLD (adjusted HR 1.71; 95% CI 1.01–2.90) were independent factors associated with HCC. When stratified according to NAFLD and MAFLD status, there was no HCC development among participants with NAFLD only during 8,936 person-years of follow-up, but this NAFLD-only group comprised 3.4%, and the majority of participants with hepatic steatosis fulfilled both NAFLD and MAFLD criteria. CONCLUSIONS: In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. For those without other chronic liver diseases, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC. IMPACT AND IMPLICATIONS: This study investigated the usefulness of newly proposed nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD), over non-alcoholic fatty liver disease (NAFLD), in terms of predicting hepatocellular carcinoma. In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. However, for those without chronic liver disease, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC. Elsevier 2023-06-28 /pmc/articles/PMC10393797/ /pubmed/37538246 http://dx.doi.org/10.1016/j.jhepr.2023.100810 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Song, Byeong Geun
Choi, Sung Chul
Goh, Myung Ji
Kang, Wonseok
Sinn, Dong Hyun
Gwak, Geum-Youn
Paik, Yong-Han
Choi, Moon Seok
Lee, Joon Hyeok
Paik, Seung Woon
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
title Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
title_full Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
title_fullStr Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
title_full_unstemmed Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
title_short Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
title_sort metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393797/
https://www.ncbi.nlm.nih.gov/pubmed/37538246
http://dx.doi.org/10.1016/j.jhepr.2023.100810
work_keys_str_mv AT songbyeonggeun metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma
AT choisungchul metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma
AT gohmyungji metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma
AT kangwonseok metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma
AT sinndonghyun metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma
AT gwakgeumyoun metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma
AT paikyonghan metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma
AT choimoonseok metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma
AT leejoonhyeok metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma
AT paikseungwoon metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma